Skip to main content
Clinical Trials/NCT02525185
NCT02525185
Completed
Not Applicable

Contractile Reserve in Dyssynchrony (CRID): A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy

Oslo University Hospital2 sites in 2 countries200 target enrollmentSeptember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Oslo University Hospital
Enrollment
200
Locations
2
Primary Endpoint
Reverse remodelling at 6 months follow-up
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Cardiac resynchronisation therapy (CRT) has been documented to be a powerful treatment in patients with severe congestive heart failure. However, 30-40% of patients receiving a CRT are non-responders. In this study the investigators will use a previously validated method to estimate myocardial segment work non-invasively by speckle-tracking echocardiography and blood pressure. Furthermore, cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement (LGE) will be performed in feasible subjects. The main purpose of the study is to determine if myocardial work by echocardiography in combination with viability assessment by LGE-CMR can predict response to CRT.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
August 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Oslo University Hospital
Responsible Party
Principal Investigator
Principal Investigator

Otto Armin Smiseth

Professor

Oslo University Hospital

Eligibility Criteria

Inclusion Criteria

  • Subject is indicated for CRT device according to European Society of Cardiology (ESC) guidelines from
  • Subject is willing to sign informed consent form and is 18 years or older.

Exclusion Criteria

  • Right bundle branch block.
  • Recent myocardial infarction, within 40 days prior to enrollment.
  • Subject underwent coronary artery bypass graft (CABG) or valve surgery, within 90 days.
  • Post heart transplantation, or is actively listed on the transplantation list, or has reasonable probability (per investigator's discretion) of undergoing transplantation in the next year
  • Implanted with a LV assist device (LVAD), or has reasonable probability (per investigator's discretion) of receiving a LVAD in the next year
  • Severe aortic stenosis (with a valve area of \<1.0 cm2 or significant valve disease expected to be operated on within study period).
  • Complex and uncorrected congenital heart disease.
  • Breastfeeding women or women of child bearing potential.
  • Enrolled in one or more concurrent studies that would confound the results of this study.
  • Impossible to obtain LV volumes by echocardiography

Outcomes

Primary Outcomes

Reverse remodelling at 6 months follow-up

Time Frame: 6 months

Measured by left ventricular end-systolic volume reduction of at least 15% assessed by echocardiography

Secondary Outcomes

  • New York Heart Association (NYHA) Class Changes(6 months)
  • Death of any cause(5 years)
  • Heart transplantation(5 years)
  • Left atrial contractile synchrony(2 years)
  • Heart failure hospitalizations(12 months)
  • Reverse remodelling at 12 months follow-up(12 months)
  • Quality of Life Changes(6 months)

Study Sites (2)

Loading locations...

Similar Trials